Does Your Job Put You at Risk for Lymphoma?

The occupation or industry in which one works may either increase or decrease risk for non-Hodgkin's lymphoma, an immune system cancer often found in middle-aged adults.



Taking a job as a roofer, printer, farmer and even a medical professional or any other job with exposure to certain chemical and biologic agents may increase the risk of non-Hodgkin's lymphoma (NHL), claims a new study in Occupational and Environmental Medicine. Researchers compared jobs between 1189 men and women with NHL and 982 men and women of similar age who did not, spanning 86 occupations in 97 industries. The investigators report an increased risk for NHL among religious workers, physical therapists, information clerks, purchasing agents and buyers, as well as workers in service, nursing/personal care, specialty outpatient care, and air transportation occupations.



By contrast, Schenk's group identified decreased risk among industrial production managers, post-secondary teachers, editors, reporters, and those working in public relations, financial records, administrative support, security and commodities, accident and health insurance, and medical and personal supply jobs.

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap